

SUPPLEMENTARY DATA

Supplementary Table1. Changes in non-LDL-C lipid parameters between the baseline and day 180 visits

		Without Diabetes									With Diabetes								
		Percent Change from Baseline									Percent Change from Baseline								
		n (%)	TC ^a	Non-HDL-C ^a	HDL-C ^a	TG ^b	VLDL-C ^b	Apo B ^a	Apo A1 ^a	Lp(a) ^b	n (%)	TC ^a	Non-HDL-C ^a	HDL-C ^a	TG ^b	VLDL-C ^b	Apo B ^a	Apo A1 ^a	Lp(a) ^b
1-dose	Placebo	57 (26)	2.6 (12.37)	3.1 (16.5)	2.5 (15.1)	10.4 (-10.1, 21.6)	10.6 (-9.8, 24.5)	2.9 (14.8)	3.1 (10.8)	1.3 (-13.5, 14.3)	6 (24)	-5.3 (7.4)	-12.4 (14.7)	16.1 (18.4)	-25.2 (-38.6, 30.1)	-26.2 (-39.1, 31.7)	-9.3 (11.4)	5.8 (8.1)	0.0 (-4.8, 15.4)
	200 mg	53 (24)	-17.2 (19.2)	-25.1 (26.8)	5.7 (14.6)	1.9 (-17.5, 18.7)	2.9 (-17.8, 19.4)	-23.1 (20.9)	3.0 (9.5)	-14.3 (-30.3, 4.3)	7 (28)	-20.2 (18.3)	-25.6 (23.3)	-5.3 (13.9)	-10.9 (-22.4, 12.2)	-9.1 (-22.8, 14.3)	-21.8 (24.1)	2.1 (7.7)	-14.3 (-21.9, 0.0)
	300 mg	54 (25)	-22.4 (15.6)	-33.8 (20.3)	9.4 (10.9)	-12.8 (-27.6, 8.8)	-12.1 (-25.0, 8.6)	-29.6 (18.0)	4.1 (9.1)	-15.0 (-25.8, 8.2)	6 (24)	-34.9 (13.1)	-48.3 (14.9)	2.8 (12.3)	-15.0 (-43.3, -6.3)	-17.4 (-42.9, 5.3)	-41.7 (14.2)	0.6 (7.2)	-5.0 (-23.1, 4.0)
	500 mg	54 (25)	-26.2 (10.6)	-36.4 (13.6)	6.4 (14.2)	-12.2 (-25.3, 9.4)	-12.1 (-24.4, 9.7)	-32.5 (12.7)	4.1 (10.9)	-16.3 (-33.8, 1.2)	6 (24)	-30.7 (12.0)	-41.7 (18.0)	11.1 (13.0)	-13.0 (-29.2, 1.1)	-13.1 (-29.7, 1.4)	-38.1 (13.4)	4.2 (12.0)	-25.5 (-40.0, 10.0)
2-dose	Placebo	52 (26)	1.2 (12.4)	2.1 (16.7)	0.4 (12.3)	-2.1 (-16.2, 25.6)	-1.5 (-16.0, 26.9)	1.6 (12.6)	1.3 (8.5)	0.6 (-10.4, 13.9)	9 (21)	-25.7 (14.9)	-3.5 (18.3)	1.0 (14.4)	-12.5 (-23.5, -8.3)	-12.3 (-26.9, 10.4)	-3.2 (15.3)	-2.6 (6.5)	-2.3 (-7.7, 12.4)
	100 mg	49 (25)	-21.7 (12.0)	-31.2 (14.5)	7.1 (12.0)	-6.3 (-17.0, 12.5)	-6.8 (-16.8, 11.9)	-27.3 (12.8)	5.3 (10.7)	-16.3 (-26.2, 1.9)	10 (24)	-25.7 (14.9)	-33.8 (18.3)	9.8 (13.5)	-5.9 (-23.4, 2.0)	-3.0 (-24.7, 5.0)	-30.6 (16.6)	6.4 (10.9)	-7.4 (-18.3, 2.9)
	200 mg	44 (22)	-25.8 (11.7)	-37.9 (16.0)	10.1 (15.5)	1.8 (-22.4, 16.0)	0.0 (-23.3, 12.0)	-34.0 (14.4)	8.3 (12.1)	-15.6 (-29.7, 5.8)	16 (38)	-29.2 (16.2)	-41.6 (19.1)	10.9 (15.3)	-5.0 (-23.7, 7.7)	-6.1 (-24.3, 8.8)	-37.8 (19.2)	9.3 (10.2)	-26.1 (-36.5, 12.8)
	300 mg	52 (26)	-32.6 (11.5)	-45.7 (15.1)	8.6 (14.9)	-16.4 (-27.3, 7.8)	-16.5 (-27.2, 7.6)	-40.6 (15.4)	5.7 (11.3)	-25.4 (-37.4, 15.0)	7 (17)	-37.5 (8.8)	-48.1 (10.5)	9.1 (15.8)	-7.2 (-21.3, 3.8)	-5.1 (-20.5, 0.0)	-43.1 (10.3)	9.9 (16.4)	-33.3 (-51.7, 15.9)

Abbreviations: Apo A1, apolipoprotein A1; Apo B, apolipoprotein B; HDL-C, high-density lipoprotein cholesterol; Lp(a), lipoprotein (a); TC, total cholesterol; TG, triglycerides; VLDL-C, very low-density lipoprotein cholesterol.

^a, mean (standard deviation) change from baseline.

^b, median (interquartile range) change from baseline.

Data are presented for the MITT population. Subjects excluded because of missing data at day 180 were as follows: 1-dose regimens, 1 in the placebo group (2%), 2 in the 300 mg inclisiran group (3%) and 6 in the 500 mg inclisiran group (9%); for the 2-dose regimens, 1 in the placebo group (2%), 3 in the 100 mg inclisiran group (5%), 3 in the 200 mg inclisiran group (5%), and 6 in the 300 mg inclisiran group (10%).